Regulatory writing for neurology
Long trials, CNS safety signals, patient-reported outcomes, and device-adjacent programs. Asthra drafts the regulated output while writers stay in control of interpretation.
Neurology trials tend to run long. Endpoints are often patient-reported, clinician-rated, or both. Safety signals — suicidality, seizure, QT changes, cognition — require specific handling and defined reporting. And where a program crosses into neuromodulation devices, the regulatory surface area expands again. Asthra drafts the heavy-lift sections across all of these document types; writers retain every clinical and regulatory call.
Where Asthra changes the shape of the work.
Long follow-up periods stretch the CSR timeline
Disease-modifying programs in neurology often require multi-year follow-up. CSR drafting for these programs means integrating data collected across reporting epochs while keeping the narrative internally consistent. Asthra reuses prior writing where evidence has not changed and flags where it genuinely has.
CNS-specific safety reporting
Suicidality assessment (C-SSRS), seizure capture, cognitive-decline tracking, and CNS-related adverse-event adjudication have precise reporting conventions. Asthra keeps that convention stable across CSRs and PSURs with sentence-level citations back to the source line-listings and adjudication records.
Patient-reported outcomes and clinician-rated scales
PROs (e.g. Beck, PANSS, MDS-UPDRS) and clinician-rated instruments need careful narrative interpretation. Asthra draws the numerical result from TFL and the instrument definition from the protocol, and keeps the two linked in the citation trail.
Neuromodulation devices add a parallel CER stream
For programs that include deep brain stimulation, VNS, or adjacent neurostimulation devices, a CER (EU MDR) runs alongside the drug or biologic program. Asthra can draft both, with consistent provenance in each.
What Asthra drafts for this area.
CSR (ICH E3)
Full CSR first draft from trial protocol, TFL, and SAP — aligned to ICH E3 with CNS-specific handling for adjudicated events.
Learn more →PSUR / PBRER / DSUR
Periodic safety reports that synthesise CNS safety signals across reporting periods, with historical-PSUR reuse where evidence is unchanged.
Learn more →CER (EU MDR)
Clinical Evaluation Reports for neuromodulation devices, with literature search and post-market surveillance woven in by section.
Learn more →CMC (eCTD Module 3)
Module 3 consolidation for small-molecule and biologic CNS programs, including stability narratives and method validation.
Learn more →Background Asthra is aware of.
Not a substitute for your regulatory strategy.
ICH E3 — structure and content of Clinical Study Reports
The structural spine of the CSR is ICH E3. Asthra aligns to E3 section ordering and content expectations out of the box.
FDA PRO Guidance and COA Framework
Patient-reported and clinician-rated outcome reporting is expected to reference the instrument definition, scoring, and psychometric basis. Asthra keeps those linked from protocol into CSR narrative.
Suicidality assessment expectations (C-SSRS)
CNS trials often carry C-SSRS capture as a standing requirement. Where adjudication data exists, Asthra cites the adjudication output rather than raw capture.
EU MDR Annex XIV (for neuromodulation)
CERs for neuromodulation devices are framed by EU MDR Annex XIV and MEDDEV 2.7/1 Rev 4. The Asthra CER template reflects this.
Neurology regulatory writing does not fit the pattern of a simple trial-and-report cycle. Long follow-up, multi-instrument endpoint batteries, adjudication, and device-adjacent work all compound the documentation load. Asthra handles the part that compounds — retrieval, citation, narrative assembly, reuse — so the writers’ time goes to the interpretive questions only they can answer.
See Asthra on a neurology document.
Bring a real source file — protocol, PSUR, CER, or Module 3 — and we'll run Asthra against it in a live demo.